The company have significantly boosted its development of an new therapy for amyloid heart disease, leveraging the compound. Initial clinical results reveals promising improvements for patients suffering from the severe disease. This effort highlights BridgeBio's commitment to addressing unmet medical demands in a heart disease space. Attruby: Bri